exatecan mesylate

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Extrahepatic Bile Duct Cancer

Conditions

Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer

Trial Timeline

Mar 1, 2000 → Apr 1, 2005

NCT ID

NCT00005938

About exatecan mesylate

exatecan mesylate is a phase 2 stage product being developed by Daiichi Sankyo for Extrahepatic Bile Duct Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00005938. Target conditions include Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer.

What happened to similar drugs?

0 of 1 similar drugs in Extrahepatic Bile Duct Cancer were approved

Approved (0) Terminated (0) Active (1)

🔄cisplatin + gemcitabine hydrochlorideEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00055952	Phase 2	Completed	Jan 1, 2003	Apr 1, 2006	Sarcoma
NCT00055939	Phase 2	Completed	Jan 1, 2003	Apr 1, 2006	Sarcoma
NCT00017212	Phase 2	Completed	Apr 1, 2001	Sep 1, 2003	Esophageal Cancer
NCT00005938	Phase 2	Completed	Mar 1, 2000	Apr 1, 2005	Extrahepatic Bile Duct Cancer
NCT00004866	Phase 2	Completed	Jan 1, 2000	Sep 1, 2003	Cervical Cancer
NCT00004108	Phase 2	Completed	Sep 1, 1999	Apr 1, 2005	Liver Cancer
NCT00004060	Phase 2	Completed	Jul 1, 1999	Sep 1, 2000	Fallopian Tube Cancer
NCT00004046	Phase 2	Completed	Jun 1, 1999	Apr 1, 2002	Breast Cancer
NCT00003951	Phase 2	Completed	Jun 1, 1999	Apr 1, 2005	Pancreatic Cancer
NCT00004045	Phase 2	Completed	Jun 1, 1999	Aug 1, 2001	Prostate Cancer
NCT00004047	Phase 1	Completed	Jun 1, 1999	Apr 1, 2005	Leukemia

Competing Products

4 competing products in Extrahepatic Bile Duct Cancer

See all competitors

Product	Company	Stage	Hype Score
cisplatin + gemcitabine hydrochloride	Eli Lilly	Phase 3	40
Gemcitabine + Cisplatin + Durvalumab	AstraZeneca	Phase 2	42
aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracil	Merck	Phase 2	35
Gemcitabine + Cisplatin + Sorafenib	Bayer	Phase 2	32